questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines du sang
Immunoprotéines
Protéines du système du complément
Enzymes activatrices du complément
Complement C3-C5 Convertases
Complement C3-C5 Convertases : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Déficience du complément
Tests de laboratoire
Tests de complément
Hémolyse
Infections
Maladies auto-immunes
Sérum
Activité enzymatique
Symptômes
5
Éruptions cutanées
Douleurs articulaires
Troubles neurologiques
Inflammation cérébrale
Infections bactériennes
Maladies auto-immunes
Déficience du complément
Symptômes cliniques
Prévention
5
Prévention
Diagnostic précoce
Alimentation équilibrée
Nutrition
Suivi médical
Complications
Conseils génétiques
Transmission héréditaire
Traitements
5
Immunoglobulines
Antibiotiques
Médicaments anti-inflammatoires
Inhibiteurs du complément
Transfusions sanguines
Protéines du complément
Thérapie génique
Déficiences génétiques
Médecine personnalisée
Soins individualisés
Complications
5
Infections graves
Maladies auto-immunes
Complications réversibles
Gestion des complications
Qualité de vie
Douleurs chroniques
Complications neurologiques
Troubles cognitifs
Lésions tissulaires
Réactions inflammatoires
Facteurs de risque
5
Antécédents familiaux
Maladies auto-immunes
Infections fréquentes
Déficience du complément
Maladies génétiques
Prédisposition
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Complement C3-C5 Convertases : Questions médicales les plus fréquentes",
"headline": "Complement C3-C5 Convertases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Complement C3-C5 Convertases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-14",
"dateModified": "2025-03-09",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Complement C3-C5 Convertases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Enzymes activatrices du complément",
"url": "https://questionsmedicales.fr/mesh/D003166",
"about": {
"@type": "MedicalCondition",
"name": "Enzymes activatrices du complément",
"code": {
"@type": "MedicalCode",
"code": "D003166",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Alternative pathway C3-C5 Convertases",
"alternateName": "Complement C3-C5 Convertases, Alternative Pathway",
"url": "https://questionsmedicales.fr/mesh/D050578",
"about": {
"@type": "MedicalCondition",
"name": "Alternative pathway C3-C5 Convertases",
"code": {
"@type": "MedicalCode",
"code": "D050578",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045.387.500"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Alternative pathway complement C3 convertase",
"alternateName": "Complement C3 Convertase, Alternative Pathway",
"url": "https://questionsmedicales.fr/mesh/D051561",
"about": {
"@type": "MedicalCondition",
"name": "Alternative pathway complement C3 convertase",
"code": {
"@type": "MedicalCode",
"code": "D051561",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045.387.500.374"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Alternative pathway C5 convertase",
"alternateName": "Complement C5 Convertase, Alternative Pathway",
"url": "https://questionsmedicales.fr/mesh/D051566",
"about": {
"@type": "MedicalCondition",
"name": "Alternative pathway C5 convertase",
"code": {
"@type": "MedicalCode",
"code": "D051566",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045.387.500.750"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Classical pathway C3-C5 Convertases",
"alternateName": "Complement C3-C5 Convertases, Classical Pathway",
"url": "https://questionsmedicales.fr/mesh/D050579",
"about": {
"@type": "MedicalCondition",
"name": "Classical pathway C3-C5 Convertases",
"code": {
"@type": "MedicalCode",
"code": "D050579",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045.387.750"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Classical pathway complement C3 convertase",
"alternateName": "Complement C3 Convertase, Classical Pathway",
"url": "https://questionsmedicales.fr/mesh/D051574",
"about": {
"@type": "MedicalCondition",
"name": "Classical pathway complement C3 convertase",
"code": {
"@type": "MedicalCode",
"code": "D051574",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045.387.750.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Classical pathway C5 convertase",
"alternateName": "Complement C5 Convertase, Classical Pathway",
"url": "https://questionsmedicales.fr/mesh/D051577",
"about": {
"@type": "MedicalCondition",
"name": "Classical pathway C5 convertase",
"code": {
"@type": "MedicalCode",
"code": "D051577",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045.387.750.750"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Mannose-Binding Protein-Associated Serine Proteases",
"alternateName": "Mannose-Binding Protein-Associated Serine Proteases",
"url": "https://questionsmedicales.fr/mesh/D050606",
"about": {
"@type": "MedicalCondition",
"name": "Mannose-Binding Protein-Associated Serine Proteases",
"code": {
"@type": "MedicalCode",
"code": "D050606",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045.387.875"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Complement C3-C5 Convertases",
"alternateName": "Complement C3-C5 Convertases",
"code": {
"@type": "MedicalCode",
"code": "D050577",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "John D Lambris",
"url": "https://questionsmedicales.fr/author/John%20D%20Lambris",
"affiliation": {
"@type": "Organization",
"name": "Department of Laboratory Medicine and Pathology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA."
}
},
{
"@type": "Person",
"name": "Tom Eirik Mollnes",
"url": "https://questionsmedicales.fr/author/Tom%20Eirik%20Mollnes",
"affiliation": {
"@type": "Organization",
"name": "Research Laboratory, Nordland Hospital, 8092 Bodø, Norway."
}
},
{
"@type": "Person",
"name": "Dimitrios C Mastellos",
"url": "https://questionsmedicales.fr/author/Dimitrios%20C%20Mastellos",
"affiliation": {
"@type": "Organization",
"name": "National Center for Scientific Research 'Demokritos', Athens, Greece."
}
},
{
"@type": "Person",
"name": "Giuseppe Remuzzi",
"url": "https://questionsmedicales.fr/author/Giuseppe%20Remuzzi",
"affiliation": {
"@type": "Organization",
"name": "Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy."
}
},
{
"@type": "Person",
"name": "Markus Huber-Lang",
"url": "https://questionsmedicales.fr/author/Markus%20Huber-Lang",
"affiliation": {
"@type": "Organization",
"name": "Institute of Clinical and Experimental Trauma Immunology, University Hospital of Ulm, Ulm, Germany."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "A prospective comparative study of [",
"datePublished": "2023-02-22",
"url": "https://questionsmedicales.fr/article/36811661",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00259-023-06142-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prospective study of Na[",
"datePublished": "2022-07-21",
"url": "https://questionsmedicales.fr/article/35862646",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/0284186X.2022.2101899"
}
},
{
"@type": "ScholarlyArticle",
"name": "A prospective study to evaluate CO",
"datePublished": "2022-08-23",
"url": "https://questionsmedicales.fr/article/35997842",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10661-022-10349-5"
}
},
{
"@type": "ScholarlyArticle",
"name": "Nutrients and Dementia: Prospective Study.",
"datePublished": "2023-02-07",
"url": "https://questionsmedicales.fr/article/36839199",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/nu15040842"
}
},
{
"@type": "ScholarlyArticle",
"name": "A prospective study to compare the diagnostic accuracy of",
"datePublished": "2024-09-26",
"url": "https://questionsmedicales.fr/article/39327339",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00432-024-05953-6"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines du sang",
"item": "https://questionsmedicales.fr/mesh/D001798"
},
{
"@type": "ListItem",
"position": 5,
"name": "Immunoprotéines",
"item": "https://questionsmedicales.fr/mesh/D007162"
},
{
"@type": "ListItem",
"position": 6,
"name": "Protéines du système du complément",
"item": "https://questionsmedicales.fr/mesh/D003165"
},
{
"@type": "ListItem",
"position": 7,
"name": "Enzymes activatrices du complément",
"item": "https://questionsmedicales.fr/mesh/D003166"
},
{
"@type": "ListItem",
"position": 8,
"name": "Complement C3-C5 Convertases",
"item": "https://questionsmedicales.fr/mesh/D050577"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Complement C3-C5 Convertases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Complement C3-C5 Convertases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-02",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Complement C3-C5 Convertases",
"description": "Comment diagnostiquer une déficience en convertases C3-C5 ?\nQuels tests sont utilisés pour évaluer l'activité du complément ?\nQuels signes cliniques suggèrent une activation du complément ?\nPeut-on mesurer l'activité des convertases dans le sang ?\nQuels marqueurs biologiques sont associés aux convertases ?",
"url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Prospective+Studies#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Complement C3-C5 Convertases",
"description": "Quels symptômes indiquent une activation excessive du complément ?\nComment se manifestent les troubles liés aux convertases ?\nLes troubles du complément causent-ils des symptômes neurologiques ?\nQuels signes indiquent une déficience en C3 ?\nLes symptômes varient-ils selon le type de déficience ?",
"url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Prospective+Studies#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Complement C3-C5 Convertases",
"description": "Peut-on prévenir les déficiences en complément ?\nQuelles mesures préventives peuvent réduire les infections ?\nLes patients doivent-ils éviter certains aliments ?\nComment le suivi médical aide-t-il à prévenir les complications ?\nLes conseils génétiques sont-ils utiles pour les familles ?",
"url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Prospective+Studies#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Complement C3-C5 Convertases",
"description": "Quels traitements sont disponibles pour les déficiences en complément ?\nComment traiter une activation excessive du complément ?\nLes transfusions sanguines aident-elles en cas de déficience ?\nY a-t-il des thérapies géniques pour les déficiences en complément ?\nLes traitements sont-ils personnalisés selon le patient ?",
"url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Prospective+Studies#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Complement C3-C5 Convertases",
"description": "Quelles complications peuvent survenir avec une déficience en C3 ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles la qualité de vie ?\nLes complications neurologiques sont-elles fréquentes ?\nQuelles sont les complications liées à l'activation excessive du complément ?",
"url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Prospective+Studies#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Complement C3-C5 Convertases",
"description": "Quels facteurs augmentent le risque de déficience en complément ?\nL'âge influence-t-il le risque de troubles du complément ?\nLes infections fréquentes sont-elles un facteur de risque ?\nLe sexe joue-t-il un rôle dans les troubles du complément ?\nLes maladies génétiques augmentent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Prospective+Studies#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en convertases C3-C5 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins mesurant les niveaux de C3 et C5 peuvent indiquer une déficience."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité du complément ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests d'hémolyse et les dosages de protéines du complément sont courants."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques suggèrent une activation du complément ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des infections récurrentes ou des maladies auto-immunes peuvent indiquer une activation."
}
},
{
"@type": "Question",
"name": "Peut-on mesurer l'activité des convertases dans le sang ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests spécifiques peuvent évaluer l'activité des convertases dans le sérum."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biologiques sont associés aux convertases ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les niveaux de C3a et C5a, produits de clivage, sont des marqueurs importants."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une activation excessive du complément ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des éruptions cutanées, des douleurs articulaires et de la fièvre peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment se manifestent les troubles liés aux convertases ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent se manifester par des infections fréquentes et des réactions inflammatoires."
}
},
{
"@type": "Question",
"name": "Les troubles du complément causent-ils des symptômes neurologiques ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles neurologiques peuvent survenir en raison d'une inflammation cérébrale."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une déficience en C3 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des infections bactériennes récurrentes et des maladies auto-immunes peuvent être des signes."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type de déficience ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier selon que la déficience concerne C3 ou C5."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les déficiences en complément ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un diagnostic précoce peut aider à gérer les symptômes."
}
},
{
"@type": "Question",
"name": "Quelles mesures préventives peuvent réduire les infections ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des vaccinations et une bonne hygiène peuvent aider à réduire le risque d'infections."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils éviter certains aliments ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'y a pas de restrictions alimentaires spécifiques, mais une alimentation équilibrée est conseillée."
}
},
{
"@type": "Question",
"name": "Comment le suivi médical aide-t-il à prévenir les complications ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier permet d'identifier et de traiter rapidement les complications potentielles."
}
},
{
"@type": "Question",
"name": "Les conseils génétiques sont-ils utiles pour les familles ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les conseils génétiques peuvent aider à comprendre les risques de transmission."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les déficiences en complément ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des immunoglobulines intraveineuses et des antibiotiques prophylactiques."
}
},
{
"@type": "Question",
"name": "Comment traiter une activation excessive du complément ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments anti-inflammatoires et des inhibiteurs du complément peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Les transfusions sanguines aident-elles en cas de déficience ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les transfusions peuvent aider à restaurer les niveaux de protéines du complément."
}
},
{
"@type": "Question",
"name": "Y a-t-il des thérapies géniques pour les déficiences en complément ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches sont en cours sur les thérapies géniques pour traiter ces déficiences."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés selon le patient ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements sont souvent adaptés en fonction des besoins individuels du patient."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une déficience en C3 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des infections graves, des maladies auto-immunes et des complications rénales peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent réduire la qualité de vie en entraînant des douleurs chroniques et des limitations fonctionnelles."
}
},
{
"@type": "Question",
"name": "Les complications neurologiques sont-elles fréquentes ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications neurologiques peuvent survenir, notamment des troubles cognitifs."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications liées à l'activation excessive du complément ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des lésions tissulaires et des réactions inflammatoires peuvent se produire."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de déficience en complément ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents familiaux et certaines maladies auto-immunes augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de troubles du complément ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque peut augmenter avec l'âge en raison de la dégradation du système immunitaire."
}
},
{
"@type": "Question",
"name": "Les infections fréquentes sont-elles un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des infections fréquentes peuvent indiquer une déficience sous-jacente du complément."
}
},
{
"@type": "Question",
"name": "Le sexe joue-t-il un rôle dans les troubles du complément ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines déficiences sont plus fréquentes chez les femmes en raison de facteurs hormonaux."
}
},
{
"@type": "Question",
"name": "Les maladies génétiques augmentent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies génétiques peuvent prédisposer à des déficiences du complément."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 09/03/2025
Contenu vérifié selon les dernières recommandations médicales
7 publications dans cette catégorie
Affiliations :
Department of Laboratory Medicine and Pathology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
5 publications dans cette catégorie
Affiliations :
Research Laboratory, Nordland Hospital, 8092 Bodø, Norway.
K.G. Jebsen Thrombosis Research and Expertise Center, University of Tromsø, 9037 Tromsø, Norway.
Department of Immunology, Oslo University Hospital, University of Oslo, 0318 Oslo, Norway.
Centre of Molecular Inflammation Research, Norwegian University of Science and Technology, 7491 Trondheim, Norway; and.
Publications dans "Complement C3-C5 Convertases" :
5 publications dans cette catégorie
Affiliations :
National Center for Scientific Research 'Demokritos', Athens, Greece.
Publications dans "Complement C3-C5 Convertases" :
5 publications dans cette catégorie
Affiliations :
Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
L. Sacco Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.
Publications dans "Complement C3-C5 Convertases" :
4 publications dans cette catégorie
Affiliations :
Institute of Clinical and Experimental Trauma Immunology, University Hospital of Ulm, Ulm, Germany.
Publications dans "Complement C3-C5 Convertases" :
4 publications dans cette catégorie
Affiliations :
Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
Publications dans "Complement C3-C5 Convertases" :
3 publications dans cette catégorie
Affiliations :
Department of Immunology, Genetics and Pathology, University Uppsala, Uppsala, Sweden.
Publications dans "Complement C3-C5 Convertases" :
3 publications dans cette catégorie
Publications dans "Complement C3-C5 Convertases" :
3 publications dans cette catégorie
Affiliations :
Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France.
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Linneaus Center for Bomaterials Chemistry, Linnaeus University, Kalmar, Sweden.
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Deparment of Infection Biology, Leibniz Institute for Natural Product Research and Infection Biology, Jena, Germany.
Faculty of Life Sciences, Friedrich Schiller University Jena, Jena, Germany.
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus, Denmark.
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus, Denmark.
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Research Laboratory, Nordland Hospital, 8092 Bodø, Norway.
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus, Denmark.
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus, Denmark.
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus, Denmark.
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus, Denmark.
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Department of Biomedicine, Aarhus University, DK-8000 Aarhus, Denmark.
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus, Denmark; gra@mbg.au.dk.
Publications dans "Complement C3-C5 Convertases" :
Prostate-specific membrane antigen (PSMA)-based PET/CT imaging has limitations in the diagnosis of prostate cancer (PCa). We recruited 207 participants with suspicious PCa to perform PET/CT imaging wi...
Every participant with suspicious PCa was scanned with both [...
Of the 207 participants analyzed, 125 had cancer, and 82 were diagnosed with benign prostatic hyperplasia (BPH). The sensitivity and specificity of [...
This prospective study provided evidence for the superior accuracy of [...
This prospective study aims to assess the diagnostic test characteristics of Na[...
One hundred seventeen obese patients (BMI 46.5 ± 6.1 kg/m...
Bone metastases were confirmed in 44 patients. Patient-based optimistic diagnostic test characteristics were (sensitivity, specificity, overall accuracy): Na[...
Na[...
Ranking as one of the largest mobility modes for passengers and freight, highway transportation globally accounts for huge amounts of fossil-based energy consumption and greenhouse gas emissions. Corr...
The association of diet and nutrients with dementia risk is an interesting research topic. Middle-aged and older Europeans not diagnosed with dementia within two years of baseline were followed up and...
To explore the value of...
This research was approved by the hospital ethics review committee. Sixty-three patients with NSCLC received...
For all patients and surgical patients, the accuracies of...
This preliminary clinical study shows that...
This study is to investigate the [...
A prospective study (NCT05264688) was performed between January 2022 and July 2022. Fifty participants were scanned using [...
In total, 47 participants (mean age 59.09 ± 10.98 [range 33-80 years]) were evaluated. The [...
[...
clinicaltrials.gov: NCT 05,264,688....
There is currently no practice-based, multicenter database of poisoned patients admitted to intensive care units (ICUs). The INTOXICATE study, endorsed by the ESICM and EAPCCT, aimed to determine the ...
Ethical approval was obtained for this multicenter, prospective observational study, and data-sharing agreements were signed with each participating center. An electronic case report form was used to ...
Seventy-eight ICUs, mainly from Europe, but also from Australia and the Eastern Mediterranean, participated. A total of 2,273 patients were enrolled between November 2020 and June 2023. The median age...
The vast majority of patients survive, and approximately one third of patients do not receive any ICU-specific interventions after admission in an intensive care unit for acute intoxication. High-qual...
OSF registration ID: osf.io/7e5uy....
Principles of safe cholecystectomy include dissection of the hepatocystic triangle and identification of the bilio-vascular structures to achieve critical view of safety. The aim of the present study ...
All consecutive patients who underwent laparoscopic cholecystectomy were included in the study. Recommended techniques of safe cholecystectomy were followed. Rouviere's sulcus was classified into four...
Five hundred patients were included in the study. Critical view of safety was achieved in 463 (92.6%) patients. Type1 Rouviere's sulcus was the most common variant found in 263 (52.6%). Normal cystic ...
Wide variation in the anatomical structures is noted when principles of safe laparoscopic cholecystectomy is followed. Awareness is paramount to avoid bilio-vascular injury during surgery....
There are limited studies on the use of bronchodilators for the treatment of bronchiectasis. This study investigated the efficacy of tiotropium in patients with bronchiectasis and airflow limitation....
This study was a prospective cohort study, including 169 patients with bronchiectasis and airflow limitation from 2015 to 2019. The clinical outcomes observed in our study were the effect of tiotropiu...
After 12 months, the annual decline in the FEV...
In conclusion, prospective cohort study showed that tiotropium effectively ameliorated the annual decline in the FEV...
Diabetes is on the rise as the worldwide population ages. While physical activity can help protect against diabetes, ageing is commonly associated with reduced physical activity. This study aimed to e...